GlassScriptPhysician profile
Stephanie Barbetta
NPI 1871561969
$1,087.10
in general payments reported to CMS, 2019-2025
19 companies · $92.06 in 2025
The $92.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $109 · 2023: $444 · 2024: $442 · 2025: $92.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $203.09 | 2023-2025 | Qulipta, Vraylar |
| Novo Nordisk INC | $149.94 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $142.66 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $95.62 | 2022-2025 | |
| Harmony Biosciences LLC | $92.23 | 2023-2024 | Wakix |
| Glaxosmithkline, LLC. | $70.22 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Exact Sciences Corporation | $49.59 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $48.31 | 2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $41.10 | 2023-2024 | |
| Insulet Corporation | $35.57 | 2024 | Omnipod |
| Dynavax Technologies Corporation | $22.74 | 2022 | |
| Biogen, INC. | $22.38 | 2022 | |
| Impel Pharmaceuticals INC. | $20.01 | 2023 | Trudhesa |
| Takeda Pharmaceuticals U.S.A., INC. | $17.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.05 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $16.76 | 2023 | Rexulti, Abilify Maintena |
| Tolmar, INC. | $16.66 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.39 | 2024 | Airsupra |
| Merck Sharp & Dohme LLC | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Barbetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.